Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 2
2008 1
2009 2
2010 4
2011 3
2012 2
2015 2
2016 3
2017 9
2018 5
2020 1
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Severe vancomycin-induced anaphylactic reaction.
Kupstaite R, Baranauskaite A, Pileckyte M, Sveikata A, Kadusevicius E, Muckiene G. Kupstaite R, et al. Among authors: baranauskaite a. Medicina (Kaunas). 2010;46(1):30-3. Medicina (Kaunas). 2010. PMID: 20234160 Free article.
[Diagnosis and treatment of rheumatoid arthritis].
Misiūniene N, Baranauskaite A. Misiūniene N, et al. Among authors: baranauskaite a. Medicina (Kaunas). 2002;38(1):110-6. Medicina (Kaunas). 2002. PMID: 12474726 Free article. Lithuanian.
Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial.
Poddubnyy D, Pournara E, Zielińska A, Baranauskaite A, Jiménez AM, Sadhu S, Schulz B, Rissler M, Perella C, Marzo-Ortega H. Poddubnyy D, et al. Among authors: baranauskaite a. Ther Adv Musculoskelet Dis. 2021 Oct 22;13:1759720X211051471. doi: 10.1177/1759720X211051471. eCollection 2021. Ther Adv Musculoskelet Dis. 2021. PMID: 34707696 Free PMC article.
Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
Weinblatt ME, Baranauskaite A, Niebrzydowski J, Dokoupilova E, Zielinska A, Jaworski J, Racewicz A, Pileckyte M, Jedrychowicz-Rosiak K, Cheong SY, Ghil J. Weinblatt ME, et al. Among authors: baranauskaite a. Arthritis Rheumatol. 2018 Jan;70(1):40-48. doi: 10.1002/art.40336. Epub 2017 Nov 21. Arthritis Rheumatol. 2018. PMID: 28950421 Free PMC article. Clinical Trial.
Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results.
Weinblatt ME, Baranauskaite A, Dokoupilova E, Zielinska A, Jaworski J, Racewicz A, Pileckyte M, Jedrychowicz-Rosiak K, Baek I, Ghil J. Weinblatt ME, et al. Among authors: baranauskaite a. Arthritis Rheumatol. 2018 Jun;70(6):832-840. doi: 10.1002/art.40444. Epub 2018 Apr 24. Arthritis Rheumatol. 2018. PMID: 29439289 Free PMC article. Clinical Trial.
33 results